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Background/Aims: We investigated the clinical characteristics and prognosis of elderly patients with acute lymphoblastic 
leukemia (ALL).
Methods: We reviewed the clinical data, laboratory findings, bone marrow findings, and cytogenetic analysis of elderly 
patients (≥ 60 years) with ALL, and data of an additional 101 younger adult patients (< 60 years) with ALL were reviewed 
for comparison.
Results: Twenty-six elderly patients (≥ 60 years) and 101 younger adult patients (< 60 years) with ALL were retrospectively 
enrolled. The median follow-up duration was 6.0 months (range, 0.4 to 113.2) in the elderly patients and 21.7 months 
(range, 1.0 to 122.7) in the adult patients. In total, 34.6% (9 patients) of the elderly patients and 24.8% (25 patients) of the 
adult patients had Philadelphia chromosome positive ALL. The overall complete remission (CR) rate was much higher 
in the younger than in the elderly patients (94.1% vs. 57.7%, p < 0.001). The median overall survival (OS) of the younger 
patients (< 60 years) was 26.3 months, whereas that of the elderly patients (≥ 60 years) was 10.3 months (p = 0.003). In 
the elderly patients with ALL, T cell lineage and the presence of lymphadenopathy were significant prognostic factors for 
OS in a univariate analysis (p = 0.033 and 0.041, respectively).
Conclusions: The outcomes of Korean elderly patients with ALL were poor, and the shorter OS was mainly due to the low 
CR rate. T-cell lineage and the presence of lymphadenopathy were significant prognostic factors in Korean elderly patients 
with ALL.
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INTRODUCTION
Acute lymphoblastic leukemia (ALL) is a disease that 
was thought to incurable in the past. However, ALL en-
tered the era of cure in childhood and the era of prolonged 
survival in adults due to the introduction of central ner-
vous system treatment, hematopoietic stem-cell trans-
plantation (HSCT), intensified post-remission therapy, 
and molecularly targeted therapy such as imatinib mesyl-
ate. ALL in elderly patients aged 60 years or older includes 
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about 30% of ALL cases excluding pediatric patients [1,2]. 
The incidence of ALL in elderly patients (≥ 65 years old) is 
1.0 to 1.6 per 100,000 patients, which is much higher than 
that in patients 25-54 years old (0.6 to 0.7 per 100,000) ac-
cording to the Surveillance Epidemiology and End Results 
study [3].
The prognosis of elderly patients with ALL is poor, per-
haps due to various problems associated with older age 
such as poor performance status, decreased bone marrow 
function, and comorbidities. Previous reports demon-
strated poor survival in elderly patients with ALL, with 
complete remission (CR) rates of 45-62%, median overall 
survival (OS) of 5-7 months, and 5-year survival rates of < 
10% [4,5]. Furthermore, elderly patients with ALL may not 
receive novel agents because most clinical trials exclude 
the elderly. 
Although elderly patients with ALL should be con-
sidered a fragile and complex population and should be 
treated carefully based on clinical evidence, reports about 
the clinical characteristics and prognosis in elderly pa-
tients with ALL are insufficient [2,6-11]. No study has been 
conducted on the clinical features and prognosis of elderly 
patients with ALL in Korea, though a retrospective study 
was conducted on elderly patients with acute myelogenous 
leukemia (AML) [12]. The aim of this study was to investi-
gate the clinical features and outcomes in elderly patients 
with ALL and to identify prognostic factors compared with 
younger adult patients, particularly in Korea, which is a 
rapidly aging society. 
METHODS
Patients
Patients aged 60 years or more first diagnosed with ALL 
from January 1998 to December 2007 at Seoul National 
University Hospital were retrospectively enrolled. To in-
vestigate the differences according to age, we additionally 
enrolled younger adult patients (< 60 years) diagnosed 
with ALL during the same period at our institution. Pa-
tients who did not undergo a bone marrow examination 
were excluded. The findings of bone marrow aspirates and 
biopsy specimens including immunophenotyping and cy-
togenetics as well as clinical and laboratory findings were 
analyzed. The diagnostic criteria were the French-Ameri-
can-British morphological and cytochemical classification. 
Immunophenotyping was performed using flow cytom-
etry and immunohistochemistry, and final diagnosis was 
classified as early pre B (CD19
+, HLA-DR
+, CD10
±, CD22
±, 
CD7
-, cIg
-, sIg
-), common (CD19
+ or CD20
+, CD10
+), pre B 
(cIg
+), B (sIg
+), or T (CD7
+, CD3
+, CD5
+ or CD2
+) cell sub-
type [13]. Karyotyping was performed in 114 patients, and 
the standard G-banding technique was used in cultured 
cells aspirated from bone marrow during metaphase. We 
considered the Philadelphia chromosome (Ph) as positive 
if it was positive in at least one of three techniques: con-
ventional cytogenetics, fluorescence in situ hybridization, 
or polymerase chain reaction. 
Chemotherapy regimen
The most commonly used regimen for induction therapy 
was a VPDL regimen of vincristine (1.5 mg/m
2, D1, 8, 
15, and 22), prednisolone (40 mg/m
2 daily, D23-28 and 
tapering after D1-D22), daunorubicin (45 mg/m
2, D1-3), 
L-asparaginase (6000 units/m
2, D12-21), and a VPD regi-
men of vincristine (2 mg, D1 and 8), prednisolone (60 mg/
m
2/day, D1-14), daunorubicin (90 mg/m
2, D1-3) in elderly 
patients with ALL. The VPD regimen plus imatinib mesyl-
ate (600 mg daily) was used in Ph-positive ALL cases after 
2002. Post-remission treatment was also analyzed. The 
VP regimen (vincristine 1.5 mg/m
2 D1 and prednisolone 
40 mg/m
2 D1-5) was used in five elderly patients, and the 
VPD regimen was used in two elderly patients. Main-
tenance therapy consisted of vincristine, prednisolone, 
methotrexate, and 6-mercaptopurine.
Statistics
Statistical analyses were performed using SPSS version 
17.0 (SPSS Inc., Chicago, IL, USA) and STATA version 11 
(Stata Corp., College Station, TX, USA). Pearson’s chi-
square test for categorical data and Student’s t test for 
continuous data were used to compare the elderly patients 
and younger adult patients.  
CR was defined as < 5% blasts in bone marrow aspirates. 
OS was defined as the time from initial diagnosis to 
death or last follow-up. Leukemia-free survival (LFS) was 
calculated from CR to the time of relapse or death or last 
follow-up in those who did not relapse. Non-disease related 
mortality was defined as death due to graft-versus-host 
disease, a microbiologically proven infection, a bleeding 
event, or causes other than leukemia without evidence of 
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patients were used for the survival analysis. The analysis 
of prognostic factors for CR rate was performed using the 
chi-square test for the univariate analysis followed by a 
multiple logistic regression analysis. Cox’s proportional-
hazard model was used to identify the prognostic factors 
for OS and LFS. The survival and cumulative hazards for 
mortality were estimated by the Kaplan-Meier method. 
Factors with p < 0.20 in the univariate analysis were 
included in the multivariate analysis, and a two-sided p 
value < 0.05 was considered statistically significant.
Ethics
This study protocol was reviewed and approved by the 
Institutional Review Board of Seoul National University 
Hospital (IRB no. H-0911-052-301). The recommendations 
of the Declaration of Helsinki for biomedical research 
involving human subjects were also followed.
RESULTS
Patient characteristics
In total, 127 patients with ALL were enrolled including 
26 elderly patients (≥ 60 years) and 101 younger adult 
patients (< 60 years). The median follow-up durations were 
6.0 months (range, 0.4 to 113.2) in the elderly patients and 
Table 1. Baseline patient characteristics 
Adult ALL
(< 60 yr, n = 101)
Elderly ALL
(≥ 60 yr, n = 26)
p value
Age, yr   30 (15-58)  65 (60-82)
male gender 65 (64.4) 17 (65.4) 0.92
Initial findings
Lymphadenopathy 17 (16.8)  4 (15.4) 1.00
Hepatosplenomegaly 15 (14.9) 1 (3.8) 0.19
mediastinal mass 6 (5.9) 1 (3.8) 1.00
Weight loss 12 (11.9) 1 (3.8) 0.30
CNS involvement 2 (2.0) 0 1.00
Bleeding 8 (7.9) 0 0.21
fever 22 (21.8) 3 (11.5) 0.24
History of Malignancy 2 (2.0) 6 (23.1) 0.001
Immunophenotyping
Unknown 5 (5.0) 1 (3.8)
T-cell lineage 14 (13.9) 5 (19.2) 0.82
B-cell lineage 82 (81.2) 20 (76.9) 0.82
Early pre B 9 (9.4) 5 (20.0)
Common B 56 (58.3) 5 (20.0)
Pre B 11 (11.5) 8 (32.0)
B 6 (6.3) 2 (8.0)
Chromosomal abnormalities  51 (50.5) 14 (53.8) 0.80
Unknown 17 (16.8) 3 (11.5)
Philadelphia chromosome  25 (24.8)   9 (34.6) 0.34
Unknown 2 (2.0) 0
WBC, /μL 12,900 (500-415,000)    7,520 (700-181,200) 0.93
a
Hb, g/dL 8.6 (3.9-14.7) 9.6 (5.9-13.1) 0.023
a
LDH, IU/L  560 (126-20110)     422 (149-7180) 0.93
a
Values are presented as median (range) or number (%).
ALL, acute lymphoblastic leukemia; WBC, white blood cell; Hb, hemoglobin; LDH, lactate dehydrogenase.
aIndependent t test.Shin dy, et al. Acute lymphoblastic leukemia in elderly patients    331
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21.7 months (range, 1.0 to 122.7) in the younger patients. 
The median age of the younger patients with ALL was 30 
years (range, 15 to 58), whereas that of the elderly patients 
with ALL was 65 years (range, 60 to 82). No significant 
differences in the baseline characteristics of the two 
groups were observed, except in history of malignancy; a 
larger portion of elderly patients with ALL had a history of 
malignancy (p = 0.001). The composition of ALL subtypes 
and the frequencies of Ph status were not statistically 
significant between the two groups. The peripheral blood 
sample laboratory findings showed more severe anemia 
in younger adult patients with ALL than in the elderly 
patients (p = 0.023) (Table 1). Of 26 elderly patients with 
ALL, abnormal karyotypes were found in 14 (53.8%) (Table 
2).
Induction chemotherapy and initial response
All patients, with the exception of two elderly patients 
who received supportive care only, received induction che-
motherapy. About half of the elderly patients (12 patients, 
46.2%) received the VPDL regimen as induction therapy. 
Five elderly patients (19.2%) were administered the VPD 
Table 2. Cytogenetics of the elderly patients with acute lymphoblastic leukemia
Patient no Gender/Age Immunophenotype Karyotype
1 M/82 T Not Available
2 M/75 Early pre B  46,XY[17]
3 F/60 T 46,XX[18]
4 F/66 Common B 46,XX[6]
5 F/74 Early pre B 46,XX[4]
6 M/69 Common B 46,XY[14]
7 M/60 B 46,XY[2]
8 M/66 T 46,XY[13]
9 M/62 T 46,XY[20]
10 M/65 Common B 46,XX,t(9;22)(q34;q11.2)[8]
11 F/69 Unknown 46,XX,t(9;22)(q34;q11), -12, +22,
 der(22)t(9;22)(q34;q11)[1]/46,XX[19]
12 M/62 Early pre B 46,XY,t(9;22)(q34;q11.2)[6]/45,idm, -12,
 der(20)t(12;20)(q12;q11.2)[14]
13 M/63 Pre-B 46,XY,t(9;22)(q34;q11)[3]/46,idem,
der(9)t(2;9)(q31;p10)[8]/46,XY[7]
14 M/62 B  46,XY,t(8;14){q24.1;q32}1]/47,sl,
+idic(1)(p13),del(17)(p10)[2]/46,XY[1]
15 M/65 Pre B 46,XY,t(8;22)(q24.1;q11),t(14;18)(q32;q21)
del(18)(p11.2)[4]/47,sl,+mar[2]/46,XY[1]
16 M/66 Pre B 46,XY,t(9;22)[4]/46,XY[10]
17 F/63 Common B 44~46,XX,t(9;22)(q34;q11.2)[8]
18 M/60 Common B 44,XY,+2[2]-13[11],-20[11],der(22)t(9;22)(q34;q11.2)[11],+mar[11][cp11]
19 M/73 T 46~47, XY,del(6)(q21)[4],del(7)(q22)[5],+20[5][cp5] /46,XY[3]
20 F/67 Pre B 47,XX,t(4;11)(q21;q23),+mar[11]/48,idem,+8[3]/46,XX[2]
21 M/61 Common B 48~49,XY,+8,-20,der(?21)t(20;21)(p11.2;p11),add(22)(q13), 
+1~4mar[12]/46,XY[8]
22 M/78 Pre B 46, XY[4]
23 M/70 Common B 44~47,XY,+8,der(9;12)(q10;q10)t(9;22)(q34;q11.2),+19[cp3]/46,XY[3]
24 F/65 T Not available
25 F/62 Common B 66~67,XXX,+X,+1,-2,-3,-4,-5,del(5)(q?33q?35)×2,-7,+8,+9,der(9;21)
(q10;q10)×1~2,-12,-13,-15,-16,-17,+19,-20,+21,+22,+mar[22]/46,XX[3]
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regimen, and one (3.8%) was administered the hyper- 
CVAD (cyclophosphamide 300 mg/m
2, D1-3; vincristine 2 
mg D4,11; adriamycin 50 mg/m
2 D4; Dexamethasone 40 
mg D1-4, D11-14) regimen. The overall CR rate was much 
higher in the younger adult patients than that in the el-
derly patients (94.1% vs. 57.7%, p < 0.001). Early mortality 
within 3 months from the start of induction chemotherapy 
was remarkably higher in the elderly patients (26.9% vs. 
5.0%, p = 0.003) (Table 3). 
Post-remission therapy and treatment outcomes
The median number of post-remission consolidation 
therapy sessions was three (range, 1 to 5) in the elderly 
patients with ALL. The regimen in the elderly patients was 
vincristine and prednisolone in seven patients. Two pa-
tients received only imatinib due to severe comorbidities. 
One patient received the CALGB 9251 regimen, and the 
other patient received non-myeloablative hematopoietic 
stem cell transplantation (HSCT) from a matched sibling 
donor. Of 15 elderly patients who achieved CR, only 11 
received post-remission therapy (Fig. 1). The overall non-
disease-related mortality rate in the elderly patients was 
higher than that in the younger adult patients (Table 3, 
Fig. 2). 
Survival 
The median OS of the younger patients was 26.3 months 
(95% confidence interval [CI], 19.6 to 33.0), whereas that 
Table 3. Chemotherapy and treatment outcomes
Adult ALL 
(< 60 yr, n = 101)
Elderly ALL 
(≥ 60 yr, n = 26)
p value
First Induction chemotherapy 
regimen
VPDL 79 (78.2)  12 (46.2) 0.001
VPD 9 (8.9)    5 (19.2)
Hyper-CVAD 1 (1.0)  1 (3.8)
Others 11 (10.9)  6
a (23.1)
Supportive only  2 (7.7)
No. of induction 1 91 (90.0)  19 (73.1) 0.007
2 6 (5.9)    5 (19.2)
3 4 (4.0) 0
Imatinib 14 (13.9)    5 (20.0) 0.54
Post-remission therapy after CR 81 (80.2) 11
b (42.3) < 0.001
Cranial prophylaxis 62 (62.0)    6 (23.1) 0.001
HSCT Conventional 31 (30.7) 0 0.001
Non-myeloablative 9 (8.9)  2 (9.5)
CR CR1 88 (87.1)  13 (50.0) < 0.001
≥ CR2 7 (6.9)  2 (7.7)
Leukemia-free survival, mon       13.7 (0.3-122.5)         7.7 (0.8-112.1) 0.95
Early mortality (< 3 mon) 5 (5.0)    7 (26.9) 0.003
dead 64 (63.4)  14 (53.8) 0.374
disease related 48 (47.5)    6 (23.1)
Non-disease related 16 (15.8)  10 (38.5) 0.011
Values are presented as median (range) or number (%).
ALL, acute lymphoblastic leukemia; VPDL, vincristine/prednisolone/daunorubicin/L-asparaginase; VPD, vincristine/prednisolone/
daunorubicin; CVAD, cyclosphophamide/vincristine/adriamycin/dexamethasone; CR, complete remission; HSCT, hematopoietic stem-
cell transplantation.
aTwo patients treated with VP (vincristine/prednisolone), two patients treated with VPDC, one patient treated with CALGB 9251 regimen, 
 and one patient treated with R-CHOP (rituximab/cyclophosphamide/adriamycin/vincristine/prednisolone).
bSeven patients treated with VP based regimen, two patients treated with imatinib only, one patient treated with CALGB 9251 regimen,  
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of the elderly patients was 10.3 months (95% CI, 3.5 to 17.2) 
(p = 0.003) (Fig. 3A). The survival difference according to 
age was not reproduced in the subpopulation of patients 
with Ph-positive ALL (data not shown), but was consis-
tently found in the patients with Ph-negative ALL (Fig. 
3B). 
Survival analysis for elderly patients with ALL
Among the elderly patients, the patients who achieved 
CR1 (CR after the first induction chemotherapy) showed 
significantly longer survival compared with those who did 
not achieve CR1 (median OS, 13.1 months vs. 2.6 months; 
p = 0.001) (Fig. 3C). Furthermore, CR1 was the only in-
dependent prognostic factor for OS in elderly patients 
with ALL (p = 0.001) (data not shown). Although the OS 
of elderly patients aged 60 to 69 tended to be longer than 
that of those aged 70 or over, the difference did not reach 
statistical significance (median OS, 11.2 months vs. 3.7 
months;  p = 0.073) (Fig. 3D).
In the survival analysis using the factors at the initial 
ALL diagnosis, the probable poor prognostic factors for 
CR were age ≥ 70 years (relative rate of remission [RR], 
0.14; 95% CI, 0.013 to 1.45; p = 0.098) and leukocytosis (≥ 
30,000/µL) (RR, 6.00; 95% CI, 0.93 to 38.63; p = 0.059). 
T-cell lineage and the presence of lymphadenopathy were 
significant factors in poor prognosis for OS in the univari-
ate analysis (hazard ratio [HR], 3.11 and 3.14; 95% CI, 1.14 
to 9.34 and 1.01 to 9.99; p = 0.033 and 0.041, respectively). 
Figure 1. Treatment and outcomes of elderly patients with acute lymphoblastic leukemia (ALL). CR, complete remission; NST, non-
myeloablative stem-cell transplantation.
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T-cell lineage and Ph-positive status tended to increase the 
HR for LFS (HR, 8.49 and 4.49; 95% CI, 0.53 to 135.82 
and 0.8 to 25.21; p = 0.069 and 0.064, respectively) (Table 
4). 
Survival analysis for younger adult patients with 
ALL
Of 101 younger patients with ALL, 95 (94.1%) achieved 
CR (Table 3). The remission rate decreased in the younger 
adult patients with the T-cell lineage (RR, 0.14; 95% CI, 
0.025 to 0.78; p = 0.025). Leukocytosis (≥ 30,000/µL) and 
Ph status were independent prognostic factors for OS (HR, 
1.89 and 1.97; 95% CI, 1.15 to 3.12 and 1.13 to 3.45; p = 0.012 
and 0.017, respectively). Leukocytosis was also an inde-
pendent prognostic factor for LFS (HR, 1.85; 95 CI, 1.09 to 
3.13; p = 0.022). However, Ph was not a significant predic-
tive factor for LFS (p = 0.055) (Tables 5 and 6).
DISCUSSION
We demonstrated that poor outcomes among Korean el-
derly patients with ALL were associated a low CR rate and 
poor treatment compliance. The trend toward decreased 
OS was more profound in patients aged > 70 years than in 
those aged 60-69 years. Our result also showed that the 
prognostic factors in the elderly patients with ALL were 
somewhat different from those in the younger adult pa-
tients with ALL. The prognostic factors for OS were T-cell 
lineage and lymphadenopathy in the elderly patients with 
ALL, whereas the significant factors for OS were Ph and 
leukocytosis in adult patients with ALL.  
A previous study showed that CR was an important 
prognostic factor in Korean elderly patients with AML [12]. 
The low response to chemotherapy in the elderly pa-
tients with ALL could be related to several factors. The 
first factor may be chemotherapy intensity. Intensified 
combination induction chemotherapy can result in an 
improvement in the CR proportion, and high dose post-
remission methotrexate (MTX) or cytarabine therapy are 
effective for treating adult ALL [14-16]. However, most 
elderly patients with ALL in our study could not receive 
the post-remission therapy after the induction therapy 
with a standard or reduced dose and also could not be 
Figure 2. Cumulative hazards of disease related and non-disease-related mortality in younger adult patients (< 60 yr) with acute lym-
phoblastic leukemia (ALL) and in elderly patients (≥ 60 yr) with ALL (p = 0.001 and 0.12, respectively). Shin dy, et al. Acute lymphoblastic leukemia in elderly patients    335
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treated with intensified post-remission regimens such 
as cyclophosphamide or MTX, though they received 
post-remission therapy. The second factor may be drug 
resistance mechanisms such as the presence of multidrug 
resistance gene 1 and multidrug resistance-related protein. 
The expression of drug resistance is frequent in patients 
with ALL after induction chemotherapy [17], and it is 
possible that the expression would be greater in elderly 
patients with ALL, if the case is analogous to that for AML 
[18]. 
Although intensified induction chemotherapy was not 
introduced, and post-remission therapy was not performed 
appropriately in most elderly patients with ALL, the 
survival benefit was definite in the patients who achieved 
CR. Our study did not show a statistical difference in non-
disease-related mortality rates between the elderly and 
younger adult groups. However, the actual risk of non-
disease-related mortality might be significantly higher in 
the elderly patients considering that only a few patients 
could receive highly toxic therapy such as HSCT, and our 
Figure 3. (A) Overall survival (OS) of elderly and younger adult patients with acute lymphoblastic leukemia (ALL). OS of elderly patients 
with ALL (≥ 60 yr) was shorter than that of younger adult patients with ALL (< 60 yr) (median OS 10.3 mon vs. 26.3 mon, respectively, p 
= 0.003). (B) OS of the elderly and younger adult patients with Philadelphia chromosome (Ph)-negative ALL. OS of the elderly patients 
with Ph-negative ALL (≥ 60 yr) was shorter than that of adult patients with Ph-negative ALL (< 60 yr) (median OS, 10.3 mon vs. 29.2 
mon, respectively, p = 0.01). (C) OS according to complete remission in elderly patients with ALL. OS of elderly patients with complete 
remission was longer than that of elderly patients without complete remission (median OS, 13.1 mon vs. 2.6 mon, p = 0.001) (D) OS ac-
cording to age (60-69 yr vs. ≥ 70 yr) in elderly patients with ALL. OS of elderly patients aged 70 years or more was not significantly dif-
ferent from that of the other elderly patients (median OS, 11.2 mon vs. 3.7 mon, p = 0.073).
A
C
B
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results indicated that about half (43.8%) of non-disease-
related mortality was related to HSCT in the younger adult 
patients with ALL. 
Our results also showed that the significant prognostic 
factors in elderly patients with ALL were different from 
those in younger patients with ALL. T-cell lineage and 
lymphadenopathy were significant prognostic factors in 
the elderly patients with ALL, whereas the Ph and leuko-
cytosis were independent prognostic factors in younger 
adult patients with ALL.
While T-cell lineage ALL is less frequent in elderly 
patients according to previous studies [2,6,8,11,19], our 
results showed that T-cell lineage ALL was more frequent 
in elderly patients. A few studies have reported that pre-B 
and common B subtypes of ALL are relatively common in 
elderly patients with ALL [7,19], which was different from 
our results. We observed only a small number of B-cell 
lineage diseases (particularly common B subtype) in 
Korean elderly patients with ALL. 
Our results showed that T-cell lineage was associated 
with poor survival in elderly patients with ALL (HR for OS, 
3.11), which is inconsistent with a previous report showing 
that T-cell lineage was a positive prognostic factor [20].
Several studies have shown that old age itself is an 
independent poor prognostic factor in patients with ALL 
[4,5]. Most studies consider 60 years of age or over as 
elderly, as in our study [4,10,21,22], but some researchers 
used different criteria such as 55 or 65 years [1,6]. It is 
unclear which age criterion appropriately reflects the 
clinical characteristics of elderly patients. Some evidence 
suggests that no cutoff point has been identified for the age 
that best predicts clinical outcomes in elderly patients with 
Table 4. Univariate analysis for complete remission, overall survival, and leukemia-free survival in elderly patients 
with ALL (≥ 60 yr) (n = 26)
Complete remission Overall survival Leukemia-free survival
RR 95% CI p value  HR 95% CI p value HR 95% CI p value
Age ≥ 70 0.14 0.013-1.45 0.098 2.60 0.88-7.67 0.073 4.48   0.41-49.46 0.18
T-cell lineage 0.22 0.019-2.53 0.23 3.11   1.14-9.34 0.033 8.49      0.53-135.82 0.069
Ph(+) 3.38     0.52-21.73 0.20 1.11 0.40-3.12 0.84 4.49      0.8-25.21 0.064
Lymph adenopathy 0.21 0.018-2.33 0.20 3.14    1.01-9.99 0.041 4.48   0.41-49.46 0.18
male 0.50   0.09-2.73 0.42 1.80    0.57-5.64 0.31 1.13 0.20-6.26 0.89
fever 1.67     0.13-21.20 0.69 0.84  0.19-3.72 0.82 0.033      0.00-253.78 0.22
WBC ≥ 30,000/µL 6.00     0.93-38.63 0.059 0.50    0.17-1.46 0.19 0.99  0.17-5.98 0.99
ALL, acute lymphoblastic leukemia; RR, relative rate of remission; CI, confidence interval; HR, hazard ratio; Ph, Philadelphia 
chromosome; WBC, white blood cell. 
Table 5. Univariate analysis for complete remission, overall survival, and leukemia-free survival in younger adult 
patients (< 60 yr) with ALL (n = 101)
Complete remission Overall survival Leukemia-free survival
RR 95% CI p value HR 95% CI p value HR 95% CI p value
male 0.90 0.16-5.15 0.90 1.52 0.91-2.56 0.11 1.31 0.79-2.20 0.30
T-cell lineage 0.14 0.025-0.78 0.025 1.27 0.65-2.50 0.49 1.73 0.85-3.53 0.13
Ph(+)
a 2.15 1.25-3.72 0.006 1.65 0.93-2.91 0.087
Lymph adenopathy 0.38 0.063-2.23 0.28 1.50 0.78-2.88 0.22 1.04 0.49-2.18 0.93
fever 0.53 0.091-3.12 0.49 0.90 0.50-1.64 0.73 0.64 0.34-1.24 0.19
Hepatosplenomegaly
a 0.75 0.35-1.57 0.44 0.72 0.34-1.52 0.39
WBC ≥ 30,000/µL 1.12 0.19-6.41 0.90 1.86 1.13-3.04 0.014 1.75 1.06-2.89 0.028
ALL, acute lymphoblastic leukemia; RR, relative rate of remission; CI, confidence interval; HR, hazard ratio; Ph, Philadelphia 
chromosome; WBC, white blood cell.
aCould not calculate RR due to the existence of a cell with a count of “0”.Shin dy, et al. Acute lymphoblastic leukemia in elderly patients    337
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ALL. Robak et al. [5] showed that clinical outcomes were 
worse in elderly patients aged 70 years or older compared 
with those less than 70 years of age, which was consistent 
with our results.
The Ph-positive status increases with age in patients 
with ALL [9,23,24], and Ph-positive status was a poor 
prognostic factor in the pre-imatinib era [25,26]. Ph-
positive status is still thought to be an independent poor 
prognostic factor for survival rather than remission 
despite the introduction of imatinib for the treatment 
of Ph-positive ALL [27]. Ph status was an independent 
prognostic factor for OS in the pooled population as a 
whole in our study (data not shown), which was consistent 
with a previous report on a Chinese population [24]. The 
rate of positive Ph was 34.6% in the elderly patients in our 
study, which was similar to that in previous studies (26-
50%) [28,29]. 
Population aging is prominent in Asian countries, 
particularly Korea. According to 2006 data from the 
Korean National Statistics Office, the proportion of 
persons aged 65 and older in Korea was 7.9% in 2002 and 
is expected to climb to 14.4% in 2014, which reflects the 
most rapid change in population composition in the world 
[30]. However, no study has been performed on Korean 
elderly patients with ALL to prepare for the super-aged 
society in the near future, although a retrospective study 
has been conducted about elderly patients with AML [12]
Some limitations of this study should be noted. First, 
the small number of elderly patients enrolled in our 
study made our results descriptive rather than statistical. 
Second, the heterogeneity of induction and post-remission 
therapy due to the nature of a retrospective study was an 
obstacle to collecting data about the prognostic factors for 
clinical outcomes. Third, the definition of non-disease-
related mortality is an arguable problem in patients who 
had died due to infection and cytopenia after induction 
chemotherapy but did not achieve CR. The definition of 
non-disease-related mortality is not only disputable in the 
field of oncology [31] but is also uncertain in the field of 
hematology. 
These factors not only show the limitations of our study 
but also reflect the difficulties when studying elderly 
patients with ALL. Despite these limitations, our study 
is one of the first about Asian elderly patients with ALL. 
Further well-designed large prospective studies are 
required to better understand the clinical features and 
outcomes in Korean elderly patients with ALL.
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